IP Library Granted Patent US 10,688,182
Granted Patent B2
US 10,688,182 · App. 15/940,334 · Granted Jun 23, 2020

Monoclonal antibodies that bind to SSEA4 and uses thereof

Inventor: Lan Bo Chen (Lexington, MA)
Assignee: CHO Pharma USA, Inc.
A61K39/39558C07K16/30A61K2039/505A61K2039/51A61P35/00C07K2317/565
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,688,182
App. No.
15/940,334
Granted
Jun 23, 2020
Kind
B2
Abstract

An isolated monoclonal antibody or antigen-binding fragment that specifically binds to stage-specific embryonic antigen 4. The monoclonal antibody or antigen-binding fragment includes a heavy-chain CDR1 having the sequence of SEQ ID NO: 33 or SEQ ID NO: 40, a heavy-chain CDR2 having the sequence of SEQ ID NO: 34 or SEQ ID NO: 39, a heavy-chain CDR3 having the sequence of SEQ ID NO: 35 or SEQ ID NO: 41, a light-chain CDR1 having the sequence of SEQ ID NO: 36 or SEQ ID NO: 42, a light-chain CDR2 having the sequence of SEQ ID NO: 37 or SEQ ID NO: 43, and a light-chain CDR3 having the sequence of SEQ ID NO: 38 or SEQ ID NO: 44. Also disclosed is an anti-tumor method carried out by administering the above monoclonal antibody or antigen-binding fragment to a subject having a tumor that expresses stage-specific embryonic antigen 4. Further provided are nucleic acids encoding the above sequences and recombinant cells containing the nucleic acids.

Claims (8)

1. An isolated monoclonal antibody or antigen-binding fragment thereof comprising a heavy-chain CDR1 (H-CDR1) having the sequence of SEQ ID NO: 33, a heavy-chain CDR2 (H-CDR2) having the sequence of SEQ ID NO: 34, a heavy-chain CDR3 (H-CDR3) having the sequence of SEQ ID NO: 35, a light-chain CDR1 (L-CDR1) having the sequence of SEQ ID NO: 42, a light-chain CDR2 (L-CDR2) having the sequence of SEQ ID NO: 43, and a light-chain CDR3 (L-CDR3) having the sequence of SEQ ID NO: 44,

wherein the monoclonal antibody or antigen-binding fragment specifically binds to stage-specific embryonic antigen 4.

2. An isolated monoclonal antibody comprising a heavy-chain having the sequence of SEQ ID NO: 14 and a light-chain having a sequence selected from the group consisting of SEQ ID NO: 28, SEQ ID NO: 30, and SEQ ID NO: 32, wherein the monoclonal antibody specifically binds to stage-specific embryonic antigen 4.

3. An isolated monoclonal antibody comprising a heavy-chain having the sequence of SEQ ID NO: 2 and a light-chain having the sequence of SEQ ID NO: 4, wherein the monoclonal antibody specifically binds to stage-specific embryonic antigen 4.

4. An isolated monoclonal antibody comprising a heavy-chain having the sequence of SEQ ID NO: 6 and a light-chain having the sequence of SEQ ID NO: 8, wherein the monoclonal antibody specifically binds to stage-specific embryonic antigen 4.

5. A method for treating a tumor, the method comprising identifying a subject having a tumor and administering to the subject an effective amount of the monoclonal antibody of claim 1 , wherein cells in the tumor express stage-specific embryonic antigen 4 (“SSEA4”).

6. A method for treating a tumor, the method comprising identifying a subject having a tumor and administering to the subject an effective amount of the monoclonal antibody of claim 2 , wherein cells in the tumor express stage-specific embryonic antigen 4.

7. The method of claim 6 , wherein the light-chain sequence is SEQ ID NO: 28.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 20, 2019
From: CHEN, LAN BO
To: CHO PHARMA USA, INC.
Reel/Frame 049231/0983 →
Continuity (1)
Related Publication 20190298828A1 · Oct 3, 2019